TEE
BMRN icon

Tibra Equities Europe’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tibra Equities Europe’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,100
Closed -$938K – 17
2019
Q4 		$938K Buy
+11,100
New +$838K 0.13% 96

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Tibra Equities Europe's BMRN Position: Q1 2020 in Review

Tibra Equities Europe sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2020, closing a stake of 11,100 shares — an estimated $938K sold.

Tibra Equities Europe first reported a position in BMRN in Q4 2019 and held it in 1 quarter. The position peaked at $938K in Q4 2019. 500 funds tracked by Wall St. Rank hold BMRN as of Q1 2020.

  • Tibra Equities Europe reported no remaining BioMarin Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Tibra Equities Europe sold 11,100 BioMarin Pharmaceuticals shares in Q1 2020, an estimated $938K.
  • Tibra Equities Europe first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Tibra Equities Europe's BioMarin Pharmaceuticals position peaked at $938K in Q4 2019.
  • 500 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2020.

Based on Tibra Equities Europe's 13F filing for Q1 2020, filed 15 May 2020.